Search

Your search keyword '"van der Stelt, Mario"' showing total 398 results
Start Over Author "van der Stelt, Mario" Publication Year Range Last 10 years
398 results on '"van der Stelt, Mario"'

1. Discovery of isoquinoline sulfonamides as allosteric gyrase inhibitors with activity against fluoroquinolone-resistant bacteria

Author

Bakker, Alexander T., Kotsogianni, Ioli, Avalos, Mariana, Punt, Jeroen M., Liu, Bing, Piermarini, Diana, Gagestein, Berend, Slingerland, Cornelis J., Zhang, Le, Willemse, Joost J., Ghimire, Leela B., van den Berg, Richard J. H. B. N., Janssen, Antonius P. A., Ottenhoff, Tom H. M., van Boeckel, Constant A. A., van Wezel, Gilles P., Ghilarov, Dmitry, Martin, Nathaniel I., and van der Stelt, Mario

Published
2024
Full Text
View/download PDF

2. A monoacylglycerol lipase inhibitor showing therapeutic efficacy in mice without central side effects or dependence

Author

Jiang, Ming, Huizenga, Mirjam C. W., Wirt, Jonah L., Paloczi, Janos, Amedi, Avand, van den Berg, Richard J. B. H. N., Benz, Joerg, Collin, Ludovic, Deng, Hui, Di, Xinyu, Driever, Wouter F., Florea, Bogdan I., Grether, Uwe, Janssen, Antonius P. A., Hankemeier, Thomas, Heitman, Laura H., Lam, Tsang-Wai, Mohr, Florian, Pavlovic, Anto, Ruf, Iris, van den Hurk, Helma, Stevens, Anna F., van der Vliet, Daan, van der Wel, Tom, Wittwer, Matthias B., van Boeckel, Constant A. A., Pacher, Pal, Hohmann, Andrea G., and van der Stelt, Mario

Published
2023
Full Text
View/download PDF

3. Structural basis of selective cannabinoid CB2 receptor activation

Author

Li, Xiaoting, Chang, Hao, Bouma, Jara, de Paus, Laura V., Mukhopadhyay, Partha, Paloczi, Janos, Mustafa, Mohammed, van der Horst, Cas, Kumar, Sanjay Sunil, Wu, Lijie, Yu, Yanan, van den Berg, Richard J. B. H. N., Janssen, Antonius P. A., Lichtman, Aron, Liu, Zhi-Jie, Pacher, Pal, van der Stelt, Mario, Heitman, Laura H., and Hua, Tian

Published
2023
Full Text
View/download PDF

5. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes

Author

Alexander, Stephen PH, Fabbro, Doriano, Kelly, Eamonn, Mathie, Alistair, Peters, John A, Veale, Emma L, Armstrong, Jane F, Faccenda, Elena, Harding, Simon D, Pawson, Adam J, Sharman, Joanna L, Southan, Christopher, Davies, Jamie A, Beuve, Annie, Boison, Detlev, Brouckaert, Peter, Burnett, John C, Burns, Kathryn, Dessauer, Carmen, Friebe, Andreas, Garthwaite, John, Gertsch, Jürg, Helsby, Nuala, Izzo, Angelo A, Koesling, Doris, Kuhn, Michaela, Ostrom, Rennolds, Papapetropoulos, Andreas, Potter, Lincoln R, Pyne, Nigel J, Pyne, Susan, Russwurm, Michael, Schmidt, Harald HHW, Seifert, Roland, Stasch, Johannes‐Peter, Szabo, Csaba, van der Stelt, Mario, van der Vliet, Albert, and Watts, Val

Subjects
Pharmacology and Pharmaceutical Sciences, Biomedical and Clinical Sciences, Generic health relevance, Animals, Databases, Pharmaceutical, Enzyme Inhibitors, Humans, Hydrolases, Isomerases, Ligands, Ligases, Lyases, Oxidoreductases, Transferases, CGTP Collaborators, Pharmacology & Pharmacy, Pharmacology and pharmaceutical sciences
Abstract

The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point-in-time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.14752. Enzymes are one of the six major pharmacological targets into which the Guide is divided, with the others being: G protein-coupled receptors, ion channels, nuclear hormone receptors, catalytic receptors and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid-2019, and supersedes data presented in the 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification (NC-IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.

Published
2019

6. Multi-parameter optimization: Development of a morpholin-3-one derivative with an improved kinetic profile for imaging monoacylglycerol lipase in the brain

Author

He, Yingfang, Grether, Uwe, Taddio, Marco F., Meier, Carla, Keller, Claudia, Edelmann, Martin R., Honer, Michael, Huber, Sylwia, Wittwer, Matthias B., Heer, Dominik, Richter, Hans, Collin, Ludovic, Hug, Melanie N., Hilbert, Manuel, Postmus, Annemarieke G.J., Stevens, Anna Floor, van der Stelt, Mario, Krämer, Stefanie D., Schibli, Roger, Mu, Linjing, and Gobbi, Luca C.

Published
2022
Full Text
View/download PDF

10. Semisynthetic guanidino lipoglycopeptides with potent in vitro and in vivo antibacterial activity.

Author

van Groesen, Emma, Mons, Elma, Kotsogianni, Ioli, Arts, Melina, Tehrani, Kamaleddin H. M. E., Wade, Nicola, Lysenko, Vladyslav, Stel, Floor M., Zwerus, Jordy T., De Benedetti, Stefania, Bakker, Alexander, Chakraborty, Parichita, van der Stelt, Mario, Scheffers, Dirk-Jan, Gooskens, Jairo, Smits, Wiep Klaas, Holden, Kirsty, Gilmour, Peter S., Willemse, Joost, and Hitchcock, Christopher A.

Subjects
GRAM-positive bacterial infections, BACTERIAL cell walls, METHICILLIN-resistant staphylococcus aureus, GLYCOPEPTIDE antibiotics, ANTIBACTERIAL agents
Abstract

Gram-positive bacterial infections present a major clinical challenge, with methicillin- and vancomycin-resistant strains continuing to be a cause for concern. In recent years, semisynthetic vancomycin derivatives have been developed to overcome this problem as exemplified by the clinically used telavancin, which exhibits increased antibacterial potency but has also raised toxicity concerns. Thus, glycopeptide antibiotics with enhanced antibacterial activities and improved safety profiles are still necessary. We describe the development of a class of highly potent semisynthetic glycopeptide antibiotics, the guanidino lipoglycopeptides, which contain a positively charged guanidino moiety bearing a variable lipid group. These glycopeptides exhibited enhanced in vitro activity against a panel of Gram-positive bacteria including clinically relevant methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant strains, showed minimal toxicity toward eukaryotic cells, and had a low propensity for resistance selection. Mechanistically, guanidino lipoglycopeptides engaged with bacterial cell wall precursor lipid II with a higher binding affinity than vancomycin. Binding to both wild-type d-Ala-d-Ala lipid II and the vancomycin-resistant d-Ala-d-Lac variant was confirmed, providing insight into the enhanced activity of guanidino lipoglycopeptides against vancomycin-resistant isolates. The in vivo efficacy of guanidino lipoglycopeptide EVG7 was evaluated in a S. aureus murine thigh infection model and a 7-day sepsis survival study, both of which demonstrated superiority to vancomycin. Moreover, the minimal to mild kidney effects at supratherapeutic doses of EVG7 indicate an improved therapeutic safety profile compared with vancomycin. These findings position guanidino lipoglycopeptides as candidates for further development as antibacterial agents for the treatment of clinically relevant multidrug-resistant Gram-positive infections. Editor's summary: Vancomycin and its second-generation lipoglycopeptide derivatives work mainly by binding the peptidoglycan precursor lipid II to inhibit cell wall synthesis in Gram-positive bacteria. However, antibiotic resistance and safety concerns remain, and improved antibiotics are still needed. Van Groesen et al. report the optimization of a series of vancomycin-derived antibiotic compounds: lipoglycopeptides that bear a guanidino lipid group. This modification promoted stronger binding to the cell wall precursor lipid II, resulting in potent antibacterial activity while also showing less toxicity to mammalian cells than second-generation vancomycin derivatives. The lead candidate compound outperformed vancomycin in improving therapeutic outcome in mouse models of S. aureus thigh infection and sepsis, suggesting that guanidino lipoglycopeptides may benefit from further development. —Catherine Charneski [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. P2X7 receptor‐dependent increase in endocannabinoid 2‐arachidonoyl glycerol production by neuronal cells in culture: Dynamics and mechanism.

Author

Singh, Simar, Sarroza, Dennis, English, Anthony, Whittington, Dale, Dong, Ao, Malamas, Michael, Makriyannis, Alexandros, van der Stelt, Mario, Li, Yulong, Zweifel, Larry, Bruchas, Michael R., Land, Benjamin B., and Stella, Nephi

Subjects
CANNABINOID receptors, CELL culture, CONFOCAL fluorescence microscopy, PHOSPHOLIPASE C, GLYCERIN, NEUROLOGICAL disorders
Abstract

Background and Purpose: Neurotransmission and neuroinflammation are controlled by local increases in both extracellular ATP and the endocannabinoid 2‐arachidonoyl glycerol (2‐AG). While it is known that extracellular ATP stimulates 2‐AG production in cells in culture, the dynamics and molecular mechanisms that underlie this response remain poorly understood. Detection of real‐time changes in eCB levels with the genetically encoded sensor, GRABeCB2.0, can address this shortfall. Experimental Approach: 2‐AG and arachidonoylethanolamide (AEA) levels in Neuro2a (N2a) cells were measured by LC‐MS, and GRABeCB2.0 fluorescence changes were detected using live‐cell confocal microscopy and a 96‐well fluorescence plate reader. Key Results: 2‐AG and AEA increased GRABeCB2.0 fluorescence in N2a cells with EC50 values of 81 and 58 nM, respectively; both responses were reduced by the cannabinoid receptor type 1 (CB1R) antagonist SR141617 and absent in cells expressing the mutant‐GRABeCB2.0. ATP increased only 2‐AG levels in N2a cells, as measured by LC‐MS, and induced a transient increase in the GRABeCB2.0 signal within minutes primarily via activation of P2X7 receptors (P2X7R). This response was dependent on diacylglycerol lipase β activity, partially dependent on extracellular calcium and phospholipase C activity, but not controlled by the 2‐AG hydrolysing enzyme, α/β‐hydrolase domain containing 6 (ABHD6). Conclusions and Implications: Considering that P2X7R activation increases 2‐AG levels within minutes, our results show how these molecular components are mechanistically linked. The specific molecular components in these signalling systems represent potential therapeutic targets for the treatment of neurological diseases, such as chronic pain, that involve dysregulated neurotransmission and neuroinflammation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Discovery of a Cannabinoid CB2 Receptor Fluorescent Probe Based on a Pyridin-2-yl-benzyl-imidazolidine-2,4-dione Scaffold.

Author

de Paus, Laura V., Janssen, Antonius P.A., Halimi, Asad, van den Berg, Richard J. B. H. N., Heitman, Laura H., and van der Stelt, Mario

Subjects
FLUORESCENT probes, CANNABINOID receptors, MOLECULES, G protein coupled receptors, AMINATION, LIFE sciences
Abstract

This document discusses the development of a fluorescent probe, called compound 22, for the cannabinoid CB2 receptor. The probe was designed to visualize the receptor without the need for a toxic copper-mediated reaction. It demonstrated reasonable affinity for the CB2 receptor, selectivity over the CB1 receptor, and acted as an inverse agonist. The study also highlights the potential impact of small structural changes in compounds on the functional behavior of the CB2 receptor. This research contributes to the development of CB2 receptor-selective drugs for various applications. [Extracted from the article]

Published
2024
Full Text
View/download PDF

14. Development of Potent and Selective Monoacylglycerol Lipase Inhibitors. SARs, Structural Analysis, and Biological Characterization

Author

Butini, Stefania, primary, Grether, Uwe, additional, Jung, Kwang-Mook, additional, Ligresti, Alessia, additional, Allarà, Marco, additional, Postmus, Annemarieke G. J., additional, Maramai, Samuele, additional, Brogi, Simone, additional, Papa, Alessandro, additional, Carullo, Gabriele, additional, Sykes, David, additional, Veprintsev, Dmitry, additional, Federico, Stefano, additional, Grillo, Alessandro, additional, Di Guglielmo, Bruno, additional, Ramunno, Anna, additional, Stevens, Anna Floor, additional, Heer, Dominik, additional, Lamponi, Stefania, additional, Gemma, Sandra, additional, Benz, Jörg, additional, Di Marzo, Vincenzo, additional, van der Stelt, Mario, additional, Piomelli, Daniele, additional, and Campiani, Giuseppe, additional

Published
2024
Full Text
View/download PDF

17. Opportunities for Lipid-Based Probes in the Field of Immunology

Author

Koenders, Sebastiaan T. A., Gagestein, Berend, van der Stelt, Mario, Compans, Richard W, Series Editor, Malissen, Bernard, Series Editor, Aktories, Klaus, Series Editor, Rappuoli, Rino, Series Editor, Galan, Jorge E, Series Editor, Ahmed, Rafi, Series Editor, Palme, Klaus, Series Editor, Casadevall, Arturo, Series Editor, Garcia-Sastre, Adolfo, Series Editor, Iwasaki, Akiko, Series Editor, Akira, Shizuo, Series Editor, Cravatt, Benjamin F., editor, Hsu, Ku-Lung, editor, and Weerapana, Eranthie, editor

Published
2019
Full Text
View/download PDF

18. Biochemical and Cellular Characterization of the Function of Fluorophosphonate-Binding Hydrolase H (FphH) in Staphylococcus aureus Support a Role in Bacterial Stress Response

Author

Fellner, Matthias, primary, Walsh, Annabel, additional, Dela Ahator, Stephen, additional, Aftab, Nadia, additional, Sutherland, Ben, additional, Tan, Eng W., additional, Bakker, Alexander T., additional, Martin, Nathaniel I., additional, van der Stelt, Mario, additional, and Lentz, Christian S., additional

Published
2023
Full Text
View/download PDF

19. IMI European Lead Factory — democratizing access to high-throughput screening

Author

Jones, Philip S., Boucharens, Sylviane, McElroy, Stuart P., Morrison, Angus, Honarnejad, Saman, van Boeckel, Stan, van den Hurk, Helma, Basting, Daniel, Hüser, Jörg, Jaroch, Stefan, Ottow, Eckhard, Benningshof, Jorg, Folmer, Rutger H. A., Leemhuis, Frank, Kramer-Verhulst, Patricia M., Nies, Vera J. M., Orrling, Kristina M., Rijnders, Ton, Pfander, Claudia, Engkvist, Ola, Pairaudeau, Garry, Simpson, Peter B., Ortholand, Jean-Yves, Roche, Didier, Dömling, Alexander, Kühnert, Sven M., Roevens, Peter W. M., van Vlijmen, Herman, van Wanrooij, Eva J. A., Verbruggen, Christophe, Nussbaumer, Peter, Ovaa, Huib, van der Stelt, Mario, Simonsen, Klaus Baek, Tagmose, Lena, Waldmann, Herbert, Duffy, James, Finsinger, Dirk, Jurzak, Mirek, Burgess-Brown, Nicola A., Lee, Wen H., Rutjes, Floris P. J. T., Haag, Hubert, Kallus, Christopher, Mors, Hartmut, Dorval, Thierry, Lesur, Brigitte, Ramon Olayo, Fernando, Hamza, Daniel, Jones, Geraint, Pearce, Christopher, Piechot, Alexander, Tzalis, Dimitrios, Clausen, Mads H., Davis, Jeremy, Derouane, Daphné, Vermeiren, Céline, Kaiser, Markus, Stockman, Robert A., Barrault, Denise V., Pannifer, Andrew D., Swedlow, Jason R., Nelson, Adam S., Orru, Romano V. A., Ruijter, Eelco, van Helden, Steven P., Li, Volkhart M., Vries, Ton, and de Vlieger, Jon S. B.

Published
2022
Full Text
View/download PDF

21. Discovery of a NAPE-PLD inhibitor that modulates emotional behavior in mice

Author

Mock, Elliot D., Mustafa, Mohammed, Gunduz-Cinar, Ozge, Cinar, Resat, Petrie, Gavin N., Kantae, Vasudev, Di, Xinyu, Ogasawara, Daisuke, Varga, Zoltan V., Paloczi, Janos, Miliano, Cristina, Donvito, Giulia, van Esbroeck, Annelot C. M., van der Gracht, Anouk M. F., Kotsogianni, Ioli, Park, Joshua K., Martella, Andrea, van der Wel, Tom, Soethoudt, Marjolein, Jiang, Ming, Wendel, Tiemen J., Janssen, Antonius P. A., Bakker, Alexander T., Donovan, Colleen M., Castillo, Laura I., Florea, Bogdan I., Wat, Jesse, van den Hurk, Helma, Wittwer, Matthias, Grether, Uwe, Holmes, Andrew, van Boeckel, Constant A. A., Hankemeier, Thomas, Cravatt, Benjamin F., Buczynski, Matthew W., Hill, Matthew N., Pacher, Pal, Lichtman, Aron H., and van der Stelt, Mario

Published
2020
Full Text
View/download PDF

23. Structural basis of selective cannabinoid CB2 receptor activation

Author

Li, Xiaoting, primary, Chang, Hao, additional, Bouma, Jara, additional, de Paus, Laura V., additional, Mukhopadhyay, Partha, additional, Palocz, Janos, additional, Mustafa, Mohammed, additional, van der Horst, Cas, additional, Kumar, Sanjay Sunil, additional, Wu, Lijie, additional, Yu, Yanan, additional, van den Berg, Richard J. B. N., additional, Janssen, Antonius P. A., additional, Lichtman, Aron, additional, Liu, Zhi-Jie, additional, Pacher, Pal, additional, van der Stelt, Mario, additional, Heitman, Laura H., additional, and Hua, Tian, additional

Published
2023
Full Text
View/download PDF

24. A novel antifolate suppresses growth of FPGS-deficient cells and overcomes methotrexate resistance

Author

van der Krift, Felix, primary, Zijlmans, Dick W, additional, Shukla, Rhythm, additional, Javed, Ali, additional, Koukos, Panagiotis I, additional, Schwarz, Laura LE, additional, Timmermans-Sprang, Elpetra PM, additional, Maas, Peter EM, additional, Gahtory, Digvijay, additional, van den Nieuwboer, Maurits, additional, Mol, Jan A, additional, Strous, Ger J, additional, Bonvin, Alexandre MJJ, additional, van der Stelt, Mario, additional, Veldhuizen, Edwin JA, additional, Weingarth, Markus, additional, Vermeulen, Michiel, additional, Klumperman, Judith, additional, and Maurice, Madelon M, additional

Published
2023
Full Text
View/download PDF

27. Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474

Author

van Esbroeck, Annelot C. M., Janssen, Antonius P. A., Cognetta, Armand B., Ogasawara, Daisuke, Shpak, Guy, van der Kroeg, Mark, Kantae, Vasudev, Baggelaar, Marc P., de Vrij, Femke M. S., Deng, Hui, Allarà, Marco, Fezza, Filomena, Lin, Zhanmin, van der Wel, Tom, Soethoudt, Marjolein, Mock, Elliot D., den Dulk, Hans, Baak, Ilse L., Florea, Bogdan I., Hendriks, Giel, De Petrocellis, Luciano, Overkleeft, Herman S., Hankemeier, Thomas, De Zeeuw, Chris I., Di Marzo, Vincenzo, Maccarrone, Mauro, Cravatt, Benjamin F., Kushner, Steven A., and van der Stelt, Mario

Published
2017

31. Disruption of tonic endocannabinoid signalling triggers cellular, behavioural and neuroendocrine responses consistent with a stress response.

Author

Petrie, Gavin N., Balsevich, Georgia, Füzesi, Tamás, Aukema, Robert J., Driever, Wouter P. F., van der Stelt, Mario, Bains, Jaideep S., and Hill, Matthew N.

Subjects
CORTICOTROPIN releasing hormone, HYPOTHALAMUS, CELL communication, HYPOTHALAMIC-pituitary-adrenal axis, PARAVENTRICULAR nucleus
Abstract

Background and Purpose: Endocannabinoid (eCB) signalling gates many aspects of the stress response, including the hypothalamic--pituitary--adrenal (HPA) axis. The HPA axis is controlled by corticotropin releasing hormone (CRH) producing neurons in the paraventricular nucleus of the hypothalamus (PVN). Disruption of eCB signalling increases drive to the HPA axis, but the mechanisms subserving this process are poorly understood. Experimental Approach: Using an array of cellular, endocrine and behavioural readouts associated with activation of CRH neurons in the PVN, we evaluated the contributions of tonic eCB signalling to the generation of a stress response. Key Results: The CB1 receptor antagonist/inverse agonist AM251, neutral antagonist NESS243 and NAPE PLD inhibitor LEI401 all uniformly increased Fos in the PVN, unmasked stress-linked behaviours, such as grooming, and increased circulating CORT, recapitulating the effects of stress. Similar effects were also seen after direct administration of AM251 into the PVN, while optogenetic inhibition of PVN CRH neurons ameliorated stress-like behavioural changes produced by disruption of eCB signalling. Conclusions and Implications: These data indicate that under resting conditions, constitutive eCB signalling restricts activation of the HPA axis through local regulation of CRH neurons in the PVN. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

32. Inhibition of diacylglycerol lipase β modulates lipid and endocannabinoid levels in the ex vivo human placenta

Author

Berger, Natascha, primary, van der Wel, Tom, additional, Hirschmugl, Birgit, additional, Baernthaler, Thomas, additional, Gindlhuber, Juergen, additional, Fawzy, Nermeen, additional, Eichmann, Thomas, additional, Birner-Gruenberger, Ruth, additional, Zimmermann, Robert, additional, van der Stelt, Mario, additional, and Wadsack, Christian, additional

Published
2023
Full Text
View/download PDF

34. EFMC – Trends that Link Medicinal Chemistry and Chemical Biology to Translational Drug Discovery

Author

Auberson, Yves P., primary, Arimondo, Paola B., additional, Duca, Maria, additional, Essig, Sebastian, additional, Grether, Uwe, additional, Rufer, Arne C., additional, Sbardella, Gianluca, additional, Schopfer, Ulrich, additional, Torrens, Antoni, additional, van der Stelt, Mario, additional, Vauzeilles, Boris, additional, Vázquez, Olalla, additional, and Zhang, Andrew X., additional

Published
2023
Full Text
View/download PDF

37. Rapid and profound rewiring of brain lipid signaling networks by acute diacylglycerol lipase inhibition

Author

Ogasawara, Daisuke, Deng, Hui, Viader, Andreu, Baggelaar, Marc P., Breman, Arjen, den Dulk, Hans, van den Nieuwendijk, Adrianus M. C. H., Soethoudt, Marjolein, van der Wel, Tom, Zhou, Juan, Overkleeft, Herman S., Sanchez-Alavez, Manuel, Mori, Simone, Nguyen, William, Conti, Bruno, Liu, Xiaojie, Chen, Yao, Liu, Qing-song, Cravatt, Benjamin F., and van der Stelt, Mario

Published
2016

38. EFMC - trends that link medicinal chemistry and chemical biology to translational drug discovery

Author

Auberson, Yves P., Arimondo, Paola B., Duca, Maria, Essig, Sebastian, Grether, Uwe, Rufer, Arne C., Sbardella, Gianluca, Schopfer, Ulrich, Torrens, Antoni, van der Stelt, Mario, Vauzeilles, Boris, Vázquez, Olalla, and Zhang, Andrew X.

Abstract

Ground-breaking research in disease biology and continuous efforts in method development have uncovered a range of potential new drug targets. Increasingly, the drug discovery process is informed by technologies involving chemical probes as tools. Applications for chemical probes comprise target identification and assessment, as well as the qualification of small molecules as chemical starting points and drug candidates. Progress in probe chemistry has opened the way to novel assay formats and pharmaceutical compound classes. The European Federation of Medicinal Chemistry and Chemical Biology (EFMC) has launched the Chemical Biology Initiative to advance science in the field of medicinal chemistry and chemical biology, while representing all members of this extended scientific community. This review provides an overview of the many important developments in the field of chemical biology that have happened at the lively interface of academic and industrial research.

Published
2023

39. Goods and bads of endocannabinoid system as a therapeutic target: Lessons learned after 30 years

Author

Maccarrone, Mauro, Di Marzo, Vincenzo, Gertsch, Juerg, Grether, Uwe, Howlett, Allyn C, Hua, Tian, Makriyannis, Alexandros, Piomelli, Daniele, Ueda, Natsuo, and van der Stelt, Mario

Subjects
610 Medizin und Gesundheit, 570 Biowissenschaften, Biologie
Abstract

The cannabis derivative marijuana is the most widely used recreational drug in the Western world, that is consumed by an estimated 83 million individuals (~3% of the world population). In recent years, there has been a marked transformation in society regarding the risk perception of cannabis, driven by its legalization and medical use in many states in the USA and worldwide. Compelling research evidence and the FDA cannabis-derived cannabidiol approval for severe childhood epilepsy have confirmed the large therapeutic potential of cannabidiol itself, Δ9-tetrahydrocannabinol (THC) and other plant-derived cannabinoids (phytocannabinoids). Of note, our body has a complex endocannabinoid system (ECS) - made of receptors, metabolic enzymes and transporters - that is also regulated by phytocannabinoids. The first endocannabinoid to be discovered 30 years ago was anandamide (N-arachidonoyl-ethanolamine); since then, distinct elements of ECS have been the target of drug design programs aimed at curing (or at least slowing down) a number of human diseases, both in the central nervous system and at the periphery. Here, a critical review of our knowledge of the goods and bads of ECS as a therapeutic target are presented, in order to define the benefits of ECS-active phytocannabinoids and ECS-oriented synthetic drugs for human health. Significance Statement The endocannabinoid system plays important roles everywhere in our body and is either involved in mediating key processes of central and peripheral diseases or represents a therapeutic target for treatment. Understanding structure, function, and pharmacology of the components of this complex system, and in particular of key receptors (like CB1R and CB2R) and metabolic enzymes (like FAAH and MAGL), will advance our understanding of endocannabinoid signaling and activity at molecular, cellular, and system levels providing new opportunities to treat patients.

Published
2023
Full Text
View/download PDF

43. Chemical Proteomics Reveals Antibiotic Targets of Oxadiazolones in MRSA

Author

Bakker, Alexander T., primary, Kotsogianni, Ioli, additional, Mirenda, Liza, additional, Straub, Verena M., additional, Avalos, Mariana, additional, van den Berg, Richard J. B. H. N., additional, Florea, Bogdan I., additional, van Wezel, Gilles P., additional, Janssen, Antonius P. A., additional, Martin, Nathaniel I., additional, and van der Stelt, Mario, additional

Published
2022
Full Text
View/download PDF

46. Comparative Photoaffinity Profiling of Omega-3 Signaling Lipid Probes Reveals Prostaglandin Reductase 1 as a Metabolic Hub in Human Macrophages

Author

Gagestein, Berend, primary, von Hegedus, Johannes H., additional, Kwekkeboom, Joanneke C., additional, Heijink, Marieke, additional, Blomberg, Niek, additional, van der Wel, Tom, additional, Florea, Bogdan I., additional, van den Elst, Hans, additional, Wals, Kim, additional, Overkleeft, Herman S., additional, Giera, Martin, additional, Toes, René E. M., additional, Ioan-Facsinay, Andreea, additional, and van der Stelt, Mario, additional

Published
2022
Full Text
View/download PDF

48. Live‐Cell Imaging of Sterculic Acid—a Naturally Occurring 1,2‐Cyclopropene Fatty Acid—by Bioorthogonal Reaction with Turn‐On Tetrazine‐Fluorophore Conjugates**

Author

Bertheussen, Kristine, primary, van de Plassche, Merel, additional, Bakkum, Thomas, additional, Gagestein, Berend, additional, Ttofi, Iakovia, additional, Sarris, Alexi J. C., additional, Overkleeft, Herman S., additional, van der Stelt, Mario, additional, and van Kasteren, Sander I., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results